Changes in Beneficial Ownership · 4
Seer, Inc.
SEERNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-07302026_080712.xml
Filing details
- Report period
- 2026-07-28
- Issuer
- Seer, Inc.
- Issuer CIK
- 0001726445
- Trading symbol
- SEER
Reporting owner 1
- Name
- Roelofs Nicolas H PHD
- Reporting owner CIK
- 0001292341
- Relationship
- Director
- Address
- C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-07-28 | A · Form 4 | 16,500[F1] | A | 0 | 91,496 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 2.14 | 2026-07-28 | A · Form 4 | 25,000 | A | 0 | [F2] | 2036-07-28 | Class A Common Stock | 25,000 | 25,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.↩ 1
- F2
- Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.↩ 1
Signature 1
- Signed
- /s/ David Horn, by power of attorney
- Date
- 2026-07-30
Company context
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
Current securities
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- SCHEDULE 13D - filed by BML Investment Partners, L.P. regarding Seer, Inc.Nov 2, 2026
- Other EventsOct 29, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 18, 2026